Génomique du cancer et du cerveau

Recent papers from Génomique du cancer et du cerveau

1. Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armJournal of Hematology & Oncology · 2026
2. Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA studyBlood Advances · 2026
3. A prospective multicentre double-blind randomized controlled trial evaluating clinical, cognitive and neural effects of potentiation of electroconvulsive therapy by repetitive transcranial magnetic stimulation in patients with treatment-resistant depression (STIMAGNECT 2)Trials · 2026
4. Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center ExperienceHematological Oncology · 2025
5. Decipher RNA isoform combinations from minigene splicing assays and massive parallel sequencing with MAGICBioinformatics · 2025
6. Neurotoxicity of chemotherapy and brain-radiotherapy in cancer: overlapping mechanisms underlying cognitive impairment.2025
7. Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentBlood · 2025
8. Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratoriesInternational Journal of Cancer · 2025
9. High frequency repetitive transcranial magnetic stimulation for auditory verbal hallucinations in schizophrenia-spectrum disorders: a naturalistic studyFrontiers in Psychiatry · 2025
10. The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)Genetics in Medicine · 2025
11. Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaBlood Advances · 2025
12. Molecular determinants of cardiac lymphatic dysfunction in a chronic pressure-overload model2025
13. Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemiaAnnals of Hematology · 2024
14. Exploring the molecular landscape of cutaneous mixed tumors characterized by TRPS1 :: PLAG1 gene fusionThe Journal of Pathology · 2024
15. The urotensin II receptor triggers an early meningeal response and a delayed macrophage-dependent vasospasm after subarachnoid hemorrhage in male miceNature Communications · 2024
16. Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACEBlood Advances · 2024
17. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkersBMC Cancer · 2024
18. How local reference panels improve imputation in French populationsScientific Reports · 2024
19. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trialTherapeutic Advances in Urology · 2024
20. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyJournal of Clinical Oncology · 2023